Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22313846 | 0.81 | SMN1; SMN2 (0.53) | KCNH2SMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL22313074 | 0.81 | ALDH1A1 (0.31) | ALDH1A1LMNAGAAMAPTMAPK1 | |
| SCHEMBL22313076 | 0.80 | L3MBTL1 (0.33) | KCNH2SMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL22313663 | 0.79 | SMN1; SMN2 (0.36) | KCNH2SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL22313670 | 0.79 | ENPP2 (0.44) | LMNAMAPT | |
| SCHEMBL22313502 | 0.79 | NOTUM (0.41) | KCNH2SMN1; SMN2MAPT | |
| SCHEMBL22313770 | 0.79 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL22313485 | 0.78 | KCNH2 (0.40) | KCNH2SMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL22313775 | 0.77 | KCNH2 (0.39) | KCNH2SMN1; SMN2MAPT | |
| SCHEMBL22313847 | 0.76 | NOTUM (0.40) | SMN1; SMN2ALDH1A1LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11162101-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | KCNH2 4616/4885SMN1; SMN2 123/4885ALDH1A1 4181/4885 |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | KCNH2 4616/4885SMN1; SMN2 123/4885ALDH1A1 4181/4885 |
| US-11162101-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | KCNH2 4616/4885SMN1; SMN2 123/4885ALDH1A1 4181/4885 |
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | KCNH2 4616/4885SMN1; SMN2 123/4885ALDH1A1 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.